Adzynma

Apadamtase alfa (ADAMTS13) is an enzyme belonging to the group of plasma zinc metalloproteinases.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ This enzyme is responsible for cleaving large multimeric complexes of von Willebrand factor involved in the coagulation process. The breakdown of large von Willebrand factor multimer clusters reduces the ability of this factor to bind to platelets and form microthrombi. The role of recombinant ADAMTS13 is to replace the deficient endogenous enzyme and reduce platelet consumption in the patient, ultimately protecting against the development of thrombocytopenia. The medicinal product is administered intravenously; however, peak ADAMTS13 enzymatic activity was observed one hour after administration of the active substance. The medicinal product has a protein structure and is therefore degraded into smaller peptides and amino acids, which are subsequently recycled by the body. The approximate half-life of the active substance is approximately 48 hours.